Govt flags Abhayrab rabies vaccine batch as substandard, probes if spurious, document shows

India's drug regulator has flagged a batch of Abhayrab rabies vaccine as substandard. This finding marks the second time concerns have been raised about counterfeit Abhayrab doses. The government's Central Drugs Laboratory found the vaccine did not meet potency requirements. Significant differences were noted between the sampled product and a reference sample. The regulator is investigating whether the vaccine is spurious under Indian law.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WJKZFAz
via IFTTT

Read More

Moopen family picks up additional stake in Aster DM Quality Care for Rs 350 cr

Union (Mauritius) Holdings acquired a 0.57 percent stake for Rs 350.34 crore. This acquisition increased the Moopen family's total shareholding to approximately 24.58 percent. The transaction involved purchasing equity shares from Centella Mauritius Holdings Ltd. The deal was executed at a price of Rs 760 per share on September 2. Aster DM Quality Care now operates a network of 39 hospitals across 28 cities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j6mh1zy
via IFTTT

Read More

Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar

Cipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s cancer drug Keytruda. Qilu will handle development, approvals, manufacturing and supply, while Cipla USA will commercialise the treatment in the US, as Cipla expands its oncology biosimilars portfolio.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TJnt7ON
via IFTTT

Read More

Drug cos refuse to take sole responsibility for overpricing

Indian drugmakers oppose a proposal making them solely liable for medicine overpricing. This regulatory move exempts retail chemists, hospitals, and nursing homes from penalties. Pharmaceutical groups argue this unfairly burdens manufacturers already following pricing rules. Retail chemists, however, welcome the safeguards for their members. Manufacturers believe accountability should extend to those setting the final patient price.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A9slboD
via IFTTT

Read More

Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka Bio

Cohance Lifesciences announced an eighteen million dollar investment to strengthen its antibody-drug conjugate strategy. This includes thirteen million dollars for NJ Bio, increasing Cohance's ownership to sixty-seven point three percent. An additional five million dollars will give Cohance a sixty-five percent stake in Aruka Bio. These transactions aim to integrate NJ Bio's services with Cohance's manufacturing capabilities. Completion of these strategic investments is expected by September twenty twenty-six.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j7mLd9n
via IFTTT

Read More

Max Healthcare to invest Rs 6,200 cr to reach 10,000-bed capacity in 3 years: CMD

Max Healthcare plans to expand its bed capacity to ten thousand beds. This significant expansion will involve an investment of approximately six thousand two hundred crore rupees. The company's growth is driven by increasing domestic demand and India's medical tourism prominence. Medical tourism currently represents nine percent of the company's overall business operations. This strategic move aims to address the growing healthcare needs across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4a5D6lo
via IFTTT

Read More

RPG Life Sciences subsidiary acquires Raghava Life Sciences' API biz for Rs 135 cr

RPG Active Pharma is acquiring Raghava Life Sciences' API and intermediates business. This strategic move aims to strengthen its integrated API play and manufacturing footprint. The acquisition includes twenty-two commercialized APIs and seven development-stage assets. This transaction will be executed on a going-concern basis through a slump sale.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OgsZw8E
via IFTTT

Read More